Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
about
Emerging targets and novel approaches to Ebola virus prophylaxis and treatmentThe organisation of Ebola virus reveals a capacity for extensive, modular polyploidyStructural and molecular basis for Ebola virus neutralization by protective human antibodiesAntibodies for biodefenseAnti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesEbola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusionProtective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy.Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.sGP serves as a structural protein in Ebola virus infection.Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infectionFluorescence Adherence Inhibition Assay: A Novel Functional Assessment of Blocking Virus Attachment by Vaccine-Induced AntibodiesCodon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challengesInhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.Chimeric Filoviruses for Identification and Characterization of Monoclonal AntibodiesPotent neutralizing monoclonal antibodies against Ebola virus infectionTwo synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein.Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure.Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).Complex immune correlates of protection in HIV-1 vaccine efficacy trials.Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies.Combinatorial peptide-based epitope mapping from Ebola virus DNA vaccines and infections reveals residue-level determinants of antibody binding.Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever?The structural basis for filovirus neutralization by monoclonal antibodiesSystematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to ProtectionAntibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors
P2860
Q24597625-D5985E3C-9D28-42F9-B76E-20711E7E9362Q27310373-213D53D6-F0EE-4EEB-AFD7-8AD77696E3EFQ27704188-F7B4A96F-0DDB-49FB-9B26-73F734EFF426Q28394941-6FF556AB-7200-4993-8FFB-0733AAAE318DQ30252022-5A913417-6605-4687-AFF6-03FD95E621AFQ33930497-DC6A32C4-761E-444B-A04F-51242958A356Q34057711-9BD0633D-2777-482E-963A-8300316300FCQ34079366-A45771C6-A901-4A61-ACF6-E1EECFA9EB17Q34257290-35CAC29F-1720-4E97-96B3-D8ECD1B35252Q34463780-4D3A743F-9009-44E1-89D1-F097BE93E2EBQ35107644-F1B71775-D36B-46CC-8673-E63075D4D8CCQ35299756-DD5E7E2F-AE62-498B-9791-E69F1159EA53Q35557177-EC5A4C24-CE80-4BE8-8B72-CCA33149EA1FQ35842390-295ACD1C-3DAD-409E-B9F5-4D56A4DA8734Q35919750-622D4B62-EDDC-45EC-A98D-0CBFE1714CBEQ36255716-382558A4-F2BF-499F-8830-9CC4A7C77D84Q36414333-02EE6FBF-FC2B-4F2D-86F3-28250291D997Q36736403-EED23AF6-E1E8-4110-8F82-D58D131C938FQ36903111-683D9E00-AFD0-4144-8CA2-DA9F8F1EF9BEQ36934038-02B5A194-6EA7-4AEC-BCB0-F90096B208F6Q36995725-1B9F665C-48FB-47A8-9232-97A2145846B3Q37007013-883DD0EA-7C02-491A-8220-EB91A4297116Q38098075-0379C0A5-BE3E-44F0-A142-F38FF908BA93Q38847348-0E69599C-3A5B-4EEF-A7FC-B8B502E08C9CQ38848208-4369A370-BCEA-4996-96E5-77E16DE4A5A2Q39108779-323AD97C-ED85-4892-9C16-69DA4A16E1CBQ40056187-C676C4F6-D463-4AB6-BABA-4CA821FB5646Q40122905-631B4F60-D4AA-469C-900F-94E04E5F576FQ41596421-C9F63936-EA40-4E3A-8BA5-93A5744666EBQ44092773-7CA5692B-D9EA-481E-A197-8C6E5525543FQ56536340-E24A7F24-E00E-461F-BA45-A380515A11ADQ56558172-86583AD9-710E-4EDF-ABBD-C089B735F77EQ58779740-E42CF773-0848-4FD5-AA47-908FF42069F5
P2860
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
@ast
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
@en
type
label
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
@ast
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
@en
prefLabel
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
@ast
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
@en
P2093
P2860
P1433
P1476
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
@en
P2093
Dennis R Burton
Devon J Shedlock
James M Cunningham
Michael A Bailey
Nancy J Sullivan
Paul M Popernack
P2860
P304
P356
10.1016/J.VIROL.2010.02.029
P407
P577
2010-03-20T00:00:00Z